OSR Holdings, Inc. reported on April 29, 2026, that it entered into a Global Exclusive License Agreement with BCM Europe AG, enabling BCME to develop and commercialize a cancer treatment with milestone payments up to $815 million. Additionally, a Pledge Agreement was executed, securing 9,974,728 shares as collateral for these future payments.